![]() ![]() The company’s unmatched expertise and track record in CRISPR and protein engineering have allowed it to hone its fully integrated and proprietary CRISPR technologies for efficacy, specificity, and deliverability. “Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” said Jennifer Doudna, co-inventor of CRISPR technology, Nobel Laureate, and co-founder of Scribe Therapeutics.įounded to address the issues of safety, delivery, poor editing outcomes, and an uncertain intellectual property landscape that limit current CRISPR technologies, Scribe’s evergreen engineering platform creates custom molecules specifically designed for therapeutic use within the human body. The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need. Gordon, managing partner at OrbiMed Advisors, will join Scribe’s Board of Directors. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate. ![]() Perceptive Advisors, funds and accounts advised by T. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of diseaseĪLAMEDA, Calif.–( BUSINESS WIRE)–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |